Back

Super-response to cardiac resynchronization therapy reduces appropriate implantable cardioverter-defibrillator therapy: comment—Authors’ reply

EP Europace Journal

13 November 2018
Organised by: Logo
Read full article
ESC Journals

Contributors

Ammar M Killu
Ammar M Killu

Author

Mayo Clinic Rochester , United States of America

Yong-Mei Cha
Yong-Mei Cha

Author

You may be interested in
thumbnail
Webinar
New 2021 HF guidelines - what is new for device therapies and how to optimally combine new HF drugs with ICD-CRTDs
16 February 2023
thumbnail
Congress Presentation
Catch them little to go for super response
22 May 2023
thumbnail
Congress Session
Atrioventricular block
1 April 2025
thumbnail
Congress Presentation
Impact of pre-implant cardiac magnetic resonance on arrhythmic outcomes in ICD recipients: insights from a single-center registry
13 April 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources